Literature DB >> 35129163

Derivation of the Pediatric Acute Gastroenteritis Risk Score to Predict Moderate-to-Severe Acute Gastroenteritis.

Adam C Levine1, Karen J O'Connell2, David Schnadower3, T John M VanBuren4, Prashant Mahajan5,6,7, Katrina F Hurley8, Phillip Tarr9, Cody S Olsen4, Naveen Poonai10,11, Suzanne Schuh12, Elizabeth C Powell13, Ken J Farion14,15, Robert E Sapien16, Cindy G Roskind17, Alexander J Rogers7, Seema Bhatt18, Serge Gouin19, Cheryl Vance20, Stephen B Freedman21,22.   

Abstract

OBJECTIVES: Although most acute gastroenteritis (AGE) episodes in children rapidly self-resolve, some children go on to experience more significant and prolonged illness. We sought to develop a prognostic score to identify children at risk of experiencing moderate-to-severe disease after an index emergency department (ED) visit.
METHODS: Data were collected from a cohort of children 3 to 48 months of age diagnosed with AGE in 16 North American pediatric EDs. Moderate-to-severe AGE was defined as a Modified Vesikari Scale (MVS) score ≥9 during the 14-day post-ED visit. A clinical prognostic model was derived using multivariable logistic regression and converted into a simple risk score. The model's accuracy was assessed for moderate-to-severe AGE and several secondary outcomes.
RESULTS: After their index ED visit, 19% (336/1770) of participants developed moderate-to-severe AGE. Patient age, number of vomiting episodes, dehydration status, prior ED visits, and intravenous rehydration were associated with MVS ≥9 in multivariable regression. Calibration of the prognostic model was strong with a P value of 0.77 by the Hosmer-Lemenshow goodness-of-fit test, and discrimination was moderate with an area under the receiver operator characteristic curve of 0.68 (95% confidence interval [CI] 0.65-0.72). Similarly, the model was shown to have good calibration when fit to the secondary outcomes of subsequent ED revisit, intravenous rehydration, or hospitalization within 72 hours after the index visit.
CONCLUSIONS: After external validation, this new risk score may provide clinicians with accurate prognostic insight into the likely disease course of children with AGE, informing disposition decisions, anticipatory guidance, and follow-up care.
Copyright © 2022 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Entities:  

Mesh:

Year:  2022        PMID: 35129163      PMCID: PMC9203936          DOI: 10.1097/MPG.0000000000003395

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   3.288


  29 in total

1.  Emergency Department Treatment of Children With Diarrhea Who Attend Day Care: A Randomized Multidose Trial of a Lactobacillus helveticus and Lactobacillus rhamnosus Combination Probiotic.

Authors:  Stephen B Freedman; Philip M Sherman; Andrew Willan; David Johnson; Serge Gouin; Suzanne Schuh
Journal:  Clin Pediatr (Phila)       Date:  2015-02-10       Impact factor: 1.168

2.  Evaluation of a gastroenteritis severity score for use in outpatient settings.

Authors:  Stephen B Freedman; Mohamed Eltorky; Marc Gorelick
Journal:  Pediatrics       Date:  2010-05-03       Impact factor: 7.124

3.  Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis.

Authors:  Stephen B Freedman; Sarah Williamson-Urquhart; Ken J Farion; Serge Gouin; Andrew R Willan; Naveen Poonai; Katrina Hurley; Philip M Sherman; Yaron Finkelstein; Bonita E Lee; Xiao-Li Pang; Linda Chui; David Schnadower; Jianling Xie; Marc Gorelick; Suzanne Schuh
Journal:  N Engl J Med       Date:  2018-11-22       Impact factor: 91.245

4.  Comparison of three dehydration scales showed that they were of limited or no value for assessing small children with acute diarrhoea.

Authors:  Dominika Pomorska; Piotr Dziechciarz; Esto Mduma; Joshua Gidion; Anna Falszewska; Hania Szajewska
Journal:  Acta Paediatr       Date:  2018-03-22       Impact factor: 2.299

5.  Emergency department revisits in children with gastroenteritis.

Authors:  Stephen B Freedman; Jennifer D Thull-Freedman; Maggie Rumantir; Eshetu G Atenafu; Derek Stephens
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-11       Impact factor: 2.839

6.  Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study.

Authors:  Marie Van der Wielen; Carlo Giaquinto; Leif Gothefors; Christel Huelsse; Frédéric Huet; Martina Littmann; Melanie Maxwell; José M P Talayero; Peter Todd; Miguel T Vila; Luigi Cantarutti; Pierre Van Damme
Journal:  BMC Fam Pract       Date:  2010-03-15       Impact factor: 2.497

Review 7.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.

Authors:  Gary S Collins; Johannes B Reitsma; Douglas G Altman; Karel G M Moons
Journal:  BMJ       Date:  2015-01-07

8.  Empirically Derived Dehydration Scoring and Decision Tree Models for Children With Diarrhea: Assessment and Internal Validation in a Prospective Cohort Study in Dhaka, Bangladesh.

Authors:  Adam C Levine; Justin Glavis-Bloom; Payal Modi; Sabiha Nasrin; Soham Rege; Chieh Chu; Christopher H Schmid; Nur H Alam
Journal:  Glob Health Sci Pract       Date:  2015-08-18

9.  External validation and comparison of three pediatric clinical dehydration scales.

Authors:  Joshua Jauregui; Daniel Nelson; Esther Choo; Branden Stearns; Adam C Levine; Otto Liebmann; Sachita P Shah
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

10.  Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial.

Authors:  Stephen B Freedman; Sarah Williamson-Urquhart; Suzanne Schuh; Philip M Sherman; Ken J Farion; Serge Gouin; Andrew R Willan; Ron Goeree; David W Johnson; Karen Black; David Schnadower; Marc H Gorelick
Journal:  Trials       Date:  2014-05-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.